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ABSTRACT  
 
The origin and nature of cognitive processes are strongly associated with synchronous 
rhythmic activity in the brain. Gamma oscillations that span the frequency range of 30–80 Hz 
are particularly important for sensory perception, attention, learning, and memory. These 
oscillations occur intrinsically in brain regions, such as the hippocampus, that are directly 
linked to memory and disease. It has been reported that gamma and other rhythms are 
impaired in brain disorders such as Alzheimer’s disease, Parkinson’s disease, and 
schizophrenia; however, little is known about how these oscillations are affected. 
In the studies contained in this thesis, we investigated a possible involvement of toxic 
Amyloid-beta (Aβ) peptide associated with Alzheimer’s disease in degradation of gamma 
oscillations and the underlying cellular mechanisms in rodent hippocampi. We also aimed to 
prevent possible Aβ-induced effects by using specially designed molecular tools known to 
reduce toxicity associated with Aβ by interfering with its folding and aggregation steps.  
Using electrophysiological techniques to study the local field potentials and cellular 
properties in the CA3 region of the hippocampus, we found that Aβ in physiological 
concentrations acutely degrades pharmacologically-induced hippocampal gamma oscillations 
in vitro in a concentration- and time-dependent manner. The severity of degradation also 
increased with the amount of fibrillar Aβ present. 
We report that the underlying cause of degradation of gamma oscillations is Aβ-induced 
desynchronization of action potentials in pyramidal neurons and a shift in the equilibrium of 
excitatory-inhibitory synaptic transmission. Using specially designed molecular tools such as 
Aβ-binding ligands and molecular chaperones, we provide evidence that Aβ-induced effects 
on gamma oscillations, cellular firing, and synaptic dynamics can be prevented. We also 
show unpublished data on Aβ effects on parvalbumin-positive baskets cells or fast-spiking 
interneurons, in which Aβ causes an increase in firing rate during gamma oscillations. This is 
similar to what is observed in neighboring pyramidal neurons, suggesting a general 
mechanism behind the effect of Aβ.  
The studies in this thesis provide a correlative link between Aβ-induced effects on excitatory 
and inhibitory neurons in the hippocampus and extracellular gamma oscillations, and identify 
the A aggregation state responsible for its toxicity. We demonstrate that strategies aimed at 
preventing peptide aggregation are able to prevent the toxic effects of Aβ on neurons and 
gamma oscillations. The studies have the potential to contribute to the design of future 
therapeutic interventions that are aimed at preserving neuronal oscillations in the brain to 
achieve cognitive benefits for patients. 
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1 LAYPERSON’S INTRODUCTION  
 
The mammalian brain is one of the most intriguing multifunctional organs to have evolved over 
several million years. It enables us to move, see, perceive, understand, memorize, and decide; 
actions which allow for the achievement of favorable outcomes. The dynamism and 
multiplicity with which the brain works is intriguing. However, our understanding of brain 
functions and disorders are limited due to the brain’s complexity. Research on levels ranging 
from single proteins to neurons and neuronal networks attempts to link molecular and cellular 
behavior found in the brain to specific behaviors. 
Neurons are the primary components of the brain and number over 100 billion, producing 
electrical and chemical signals that are critical for information processing. Neurons are 
connected to one another and organized in specialized circuits and networks where information 
processing takes place. Information processing in these circuits gives rise to the perception of 
the external world, attention, and the ability to act voluntarily. It is therefore essential to 
understand how individual neurons function, how they are organized into signaling pathways, 
and how they communicate with each other through chemical and electrical signals. Signals 
from multiple neurons can synchronize, producing activity with rhythmic properties, called 
oscillations. An analogy for neuronal network oscillations and their role in cognition is an 
orchestra. In an orchestra, individual musicians play in coordination to produce music. If a few 
players play asynchronously, the correct music is not produced. Similarly, neurons in networks 
have to work in a coordinated fashion to enable various cognitive tasks. Such oscillations can 
be classified into unique frequency bands associated with specific behaviors. One of the well-
studied oscillations is the gamma rhythm, which is important for learning, memory and 
cognition. An understanding of the way neurons and neuronal oscillations function can enable 
us to identify mechanisms underlying neurodegenerative disorders and find possible cures.  
The hippocampus is an important part of the cortex, known for its role in spatial navigation and 
memory. It is also one of the main areas affected during neurodegenerative disorders such as 
Alzheimer’s disease (AD), affecting memory formation, consolidation and retrieval. The 
hippocampus has a highly structured laminar architecture with unique neurons in each layer, 
coordinated neuronal networks, and intrinsic properties. Consequently, the hippocampus has 
the ability to generate oscillations, making it an interesting area of study concerning neuronal 
communication in healthy individuals and AD patients. The oscillatory properties of the 
hippocampus and other regions of the cortex are dependent on a network of connected neurons 
which mutually excite and inhibit each other. The balance of excitation and inhibition in 
neuronal networks is delicate and, if disturbed, may result in abnormal brain functioning.  
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Advancements in science have enabled the removal of specific regions of the brain, such as the 
hippocampus, to study them in isolation. While maintaining the regions in artificial laboratory 
conditions akin to physiological conditions, it is possible to study electrical signals propagated 
between neurons in local circuits, as well as in wider networks, using electrophysiological 
techniques. 
Brain disorders such as AD are a growing concern for society as they place a burden on 
affected individuals and their relatives, and require many resources for care. Individuals with 
AD show poor memory formation and it has been reported that neuronal oscillations are altered 
in AD patients. Considering the hippocampus’ role in memory formation and its relevance in 
AD research, this thesis examines chemically-induced hippocampal gamma oscillations in an 
AD experimental model. 
Amyloid-beta (Aβ) is a peptide that misfolds and aggregates in AD and has been implicated in 
triggering and propagating the disease. This misfolded peptide has the ability to self-assemble 
and polymerize into larger forms - fibrils - that are variably toxic for neurons. Aβ is first 
released as a monomer with an unstructured and/or -helical secondary peptide structure. Over 
time, these monomers can change their secondary structure to a -sheet form, which can then 
aggregate to form oligomers (believed to be the most toxic), proto-fibrils, and fibrils. The latter 
can then form the plaques typical of AD.  
We acutely exposed hippocampal brain slices to highly purified Aβ and studied its effect on 
gamma oscillations and neuronal characteristics. We report that Aβ, especially oligomeric and 
fibrillar forms cause a significant reduction in the power or strength of gamma oscillations in 
the CA3 region of the hippocampus. The effect is dependent on the concentration and exposure 
time of Aβ. Further investigation into individual neurons that contribute to gamma oscillations 
revealed that Aβ causes i) a change in the electrical properties of neurons and ii) an imbalance 
in the excitation-inhibition relationship within the network. 
In an attempt to prevent these aberrations, we used molecular tools known to specifically bind 
to Aβ and prevent its cytotoxic effects. The molecular tools included i) designed Aβ-binding 
ligands, known to stabilize Aβ in its -helical secondary structure, thereby favoring these forms 
over a -sheet secondary structure; and ii) naturally occurring molecular chaperones containing 
the BRICHOS domain that act late in the Aβ polymerization process, delaying the formation of 
fibrils. When these molecular tools were applied, we observed that A failed to disrupt gamma 
oscillations, electrical properties of pyramidal neurons (PNs) or the balance of excitation and 
inhibition between neurons. 
This thesis offers insights into changes in cellular and network mechanisms caused by Aβ in an 
AD model and suggests methods to maintain normal gamma oscillations using specially 
designed molecular tools. Further studies of the described mechanisms in mouse models of the 
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disease, including behavioral assessments, are necessary for the clinical translation of the 
results. 
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2 INTRODUCTION 
 
After 17 weeks of prenatal development, the human brain begins to show neuronal activity. The 
electrical signals generated represent the status of the brain and the entire body. Neurons are the 
source of these signals, receiving stimuli via dendrites, processing these signals internally, and 
transmitting them across their axons as action potentials (APs) over both short and long 
distances. The transmission of APs is a critical aspect of information processing in the brain. 
Early in the development of neurons, networks and specialized microcircuits with other 
neurons are readily formed. Information processing in the brain happens at every conceivable 
level, including the network level in the hippocampus, the focus of this thesis. In a network, 
individual neurons are connected to each other, forming microcircuits, influence each other’s 
output, and as such function interdependently. These microcircuits are well connected at 
various levels of organization. For example, a microcircuit in the hippocampus receives input 
from other microcircuits nearby, projections from the septum, brainstem, and long-range 
projections from other cortical areas.  
Information processing at the neuronal level relies heavily on synaptic currents generated at 
synapses in response to connected neurons’ APs. The resting membrane potential (Em) of 
neurons can change dynamically depending on the type of synaptic transmission they receive. 
These transmissions can be either excitatory or inhibitory in nature, leading to excitatory 
postsynaptic potentials (EPSPs) or inhibitory postsynaptic potentials (IPSPs), respectively. 
These primary transmembrane potentials integrate and, upon reaching a threshold, generate an 
active output or action potential, AP (the neuron “fires”). The synchronous activity of a group 
of neurons and subthreshold membrane oscillations can give rise to rhythmicity in the local 
field potential (LFP) (1-3). These rhythmic events or oscillations are believed to be critical for 
information processing in the brain (4). 
Neurons have special properties, which enable them to resonate and oscillate at multiple 
frequencies (5). The timing of this activity is critical for information processing in neuronal 
networks (5). For effective cortical information processing to happen, a pattern of coherence 
among neuronal groups is required (6). This coherent neuronal activity is sensitive to synaptic 
inputs and modulates rhythmic excitability, which determines spike output (6). The rhythmic 
spike output provides temporal windows for neuronal communication and it is widely viewed 
that coherently oscillating neuronal activity is important for cortical information processing (5-
7). It has been shown that systemic functions associated with neuronal network activity are 
critically dependent on synaptic modifications at the command of pre- and postsynaptic spiking 
that occurs within a critical window of tens of milliseconds (8). The rhythmic neuronal patterns 
or neuronal oscillations form an important interface between cellular activity and larger 
systemic functions such as cognition and behavior. 
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2.1 The hippocampus and its relevance to health and disease 
The hippocampus, part of the limbic system, is a seahorse-like structure in the medial temporal 
lobe that is well connected to other subcortical areas and the contralateral hippocampal region. 
The hippocampus has a profound role in the consolidation of short- to long-term memory, 
cognition and spatial navigation (9-12). It is among the most well studied areas of the 
mammalian brain and has provided a wealth of information concerning neurons and neuronal 
networks in health and disease. One of the most intriguing case studies of the 20
th
 century was 
the epileptic patient Henry Molasion who underwent surgery to remove his medial temporal 
lobes. Following the surgery, the role of the hippocampus in new, declarative memory 
formation became evident (13). Moreover, the Nobel Prize in Physiology or Medicine in 2014 
was awarded to John O’Keefe, May-Britt Moser, and Edvard Moser for demonstrating how a 
group of neurons in the hippocampus, called place cells, and a group of neurons in the 
entorhinal cortex (EC), called grid cells, form a physiological substrate for spatial navigation. 
Given the role of the hippocampus in memory formation and its intrinsic ability to generate 
neuronal oscillations associated with various activities, it is an ideal brain region to study such 
rhythmic activity. 
The hippocampal formation consists of the EC; the dentate gyrus (DG); cornu ammonis (CA) 
regions CA1, CA2, and CA3; and the subiculum (figure 1). These regions are each special and 
differ slightly structurally and functionally. The PNs of layer II of the EC send axonal 
projections to excite granule cells of the DG via the perforant pathways. The granule cells 
forward the excitatory drive to PNs in the CA3 region via mossy fibers. The PNs of the CA3 
region, through axonal projections known was Schaffer Collaterals (SC), send an excitatory 
drive to the PNs of CA1, forming the trisynaptic circuit/pathway. Additionally, there is a dense 
associative network connecting the PNs of CA1, forming the main hippocampal output back to 
the EC via the subiculum. The hippocampus is abundantly rich in a variety of interneurons 
(INs), such as FSNs, axo-axonic INs, oriens–lacunosum molecular INs, and bistratified INs, all 
of which have unique parts in modulating neuronal oscillations. As discussed, INs have a 
profound role in oscillogenesis and their firing pattern is primarily synchronized through 
excitatory synaptic inputs projected from the local collaterals of PNs (14). 
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Figure 1. A hippocampal brain slice. The highly interconnected laminar architecture of the hippocampus 
possesses intrinsic properties suitable for the generation of neuronal oscillations. The prominent regions are 
(clockwise) the cornu ammonis region 1 (CA1), entorhina cortex (EC), dentate gyrus (DG), and cornu ammonis 
region 3 (CA3). The supporting structures are the lateral perforant path (LPP), medial perforant path (MPP), 
mossy fibers (MFs), and Schaffer Collaterals (SC). Figure adapted from (15).  
 
The CA1–3 regions of the hippocampus have a similar architecture with the outermost region 
being the alveus, consisting of white myelinated fibers. Further inwards is the stratum oriens 
which is rich in various types of INs. Next, the stratum pyramidale consists of a group of 
glutamatergic principle cells (PNs) in CA1, with their axons projecting to CA2 and CA3. The 
stratum radiatum can be observed inside the curve of the pyramidal cell layer, and it is rich in 
INs as well as axonal projections from CA3. The innermost layer is the stratum lacunosum-
moleculare, where the apical dendrites of PNs and axonal projections from EC terminate (16). 
The region CA3 is particularly interesting as it has been shown to consolidate episodic and 
contextual memories (17, 18), while CA1 is believed to play a role in spatial memory (19). For 
the purpose of this study, we focus on the region CA3 of the hippocampus where the most 
prominent gamma oscillation recordings are observed. 
It is clear that the hippocampus is relevant to studies relating to neurodegenerative disorders. 
The cortex and the hippocampus in particular are the earliest brain regions affected by AD (20). 
Histological examinations of the hippocampus have revealed that it is vulnerable to AD 
pathology (21) and longitudinal MRI studies have shown that substantial loss of hippocampal 
volume is observed in AD subjects (22-25). Examinations of hippocampal regions CA1-CA3 
for neuronal density in AD patients compared to healthy individuals of the same age have 
shown that CA1 and CA3 regions are particularly prone neuronal density loss (26). The 
hippocampus is relevant for studies relating to AD and sub-regions CA1 and CA3 are of 
particular interest given their role in generating gamma oscillations and implication in AD 
pathology. 
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2.2 Oscillations in neuronal networks 
Simple, synchronous neuronal activity can be observed as a result of the excitation and 
inhibition of cellular membranes’ electric potential in individual neurons. These are maintained 
through a dynamic balance of inward and outward currents (27). Larger, synchronous neuronal 
activities, such as neuronal oscillations, make use of local excitatory and inhibitory connections 
between neurons, whereby the excitatory synaptic currents increase the occurrence of APs. 
These are regulated by inhibitory synaptic currents, which maintain a dynamic balance between 
the local excitation and inhibition (1). The firing of neurons with respect to an ongoing gamma 
oscillation may provide a plausible mechanism for information processing in neuronal 
networks (28). The amplitude and frequency of oscillations are continuously modulated by 
stimuli received by the network and the behavioral state of the subject. 
Neuronal oscillations in the mammalian brain exhibit a wide range of frequencies - 0.05 Hz –
500 Hz - associated with different states of the brain (5). They are widely observed in the 
central nervous system (CNS), such as in cortices, the cerebellum, olfactory bulb, thalamus, 
hypothalamus, hippocampus and others (27, 29-31). In particular oscillations in the 
hippocampus are important and have been extensively studied for their role in various aspects 
of cognition, memory, and navigation (32, 33). The three primary oscillations in the 
hippocampus are theta (4–10 Hz), gamma (30–80 Hz) and sharp wave ripples (>80 Hz) (34-
36). Theta and gamma oscillations in the hippocampus have been implicated in many aspects of 
neuronal processing; during hippocampus-dependent behaviors (37), modulating synaptic 
plasticity (38, 39) and neuronal network function (5, 40, 41). Oscillations in different frequency 
bands can co-exist temporally and interact with each other, representing various behavioral 
states. For example, gamma oscillations have been shown to be nested within theta oscillations 
and are important for working memory, the representation of spatial sequences and long-range 
synchronization between brain regions (7, 42).  
In the hippocampus the continuous discharge of INs has been demonstrated, whereas PN 
activity is suppressed by short-term synaptic inhibition (43, 44). Following this suppression, 
population discharge of PNs takes place again and a new oscillatory cycle is initiated. 
Interneurons also play a role in controlling Ca
2+ 
spike generation in dendrites (14) and help in 
the generation of gamma oscillations in hippocampal subfields (45).  
Our primary interest is to study gamma oscillations between 30–80 Hz that are associated with 
cognitive functions such as sensory perception, visual attention, exploring environment novelty, 
spatial navigation and memory (46-49). Moreover, we explore how these gamma oscillations 
are altered in neurodegenerative disorders such as AD. It has been reported clinically that 
gamma oscillations are disturbed or disrupted in several brain disorders associated with 
cognitive decline, such as AD (46, 47, 50), Parkinson’s disease (51), and schizophrenia (52). 
This thesis focuses on possible mechanisms by which gamma oscillations are disturbed in an 
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AD model by studying individual neurons and networks that generate gamma oscillations and 
preventive and/or rescue measures that can be used to sustain normal gamma rhythms. 
What drives gamma oscillations in neuronal networks? 
It is well established that gamma oscillations are critically dependent on GABAergic inhibitory 
synaptic transmission (53, 54). Interneurons with their widespread axonal plexus perform the 
synchronous inhibition of multiple neurons, such as PNs, in their network (54). Interneurons 
are highly diverse and studies have shown that different subtypes of INs contribute distinctly to 
neuronal network dynamics (55). Interneurons can be classified into groups based on different 
criteria, including their expression pattern of calcium-binding proteins (56). Among them, 
parvalbumin-expressing (PV+) perisomatic-targeting basket cells or FSNs and cholecystokinin-
expressing (CCK+) IN subtypes have been shown to be particularly relevant to neuronal 
oscillations (56, 57). In structures such as the neocortex and hippocampus, phasic inhibition is 
regulated by a heterogeneous population of fast-spiking INs (FSNs) or basket cells (1, 7). These 
FSNs fire in synchrony with or, in other terms, are phase-locked to gamma oscillations and are 
important for generating the oscillations both in vivo (30) and in vitro (58). Currently, there are 
two popular mechanistic explanations for the generation of gamma oscillations: The Pyramidal-
Interneuron Network Gamma (PING) model and the Interneuron-Network gamma (ING) 
model (53) (figure 2). The PING model posits that excitatory PNs provide feedback excitation 
and INs provide a phasic drive to pace the oscillation of the network, suggesting that reciprocal 
connections between INs and PNs are responsible for oscillations. This is supported by in vivo 
and in vitro findings which show that PNs fire synchronously in the gamma frequency and their 
activity precedes FSN firing (4, 59, 60) and that the selective ablation of AMPA receptors on 
FSNs weakens gamma oscillations (61), respectively. The ING model suggests that a group of 
INs alone in a network is sufficient to establish and maintain gamma oscillations. The rationale 
behind this model is that INs, by virtue of mutual inhibition, are capable of generating 
oscillations. The ING model is supported by studies where tonic excitation of INs induced 
gamma oscillations which continued to maintain oscillations even after the excitatory synaptic 
transmission was blocked (58, 62). The requirements for ING model generation of gamma 
oscillation are mutual synaptic connections among INs in the network, tonic firing, and GABA 
receptor-mediated conductance.  
Although ING models can be replicated in vitro and in vivo, a neuronal network model for the 
generation of gamma oscillations that relies on the PING model is a more plausible mechanism 
as excitatory neurons are an integral part of cortical networks. Undoubtedly, inhibitory INs are 
essential for the generation of gamma oscillations as they pace these oscillations in the neuronal 
networks and different types are able to modulate the firing of APs at preferred phases of the 
oscillations (2, 58). As the targets of FSNs are the somata of PNs, they are able to exert a strong 
inhibitory effect on the initial axon segment. Additionally, INs, through gap-junctions, 
modulate highly coordinated firing in other neurons (63, 64) and express the rapidly 
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deactivating potassium channel Kv3.1, which has an important role in regulating every cycle of 
gamma oscillations (57, 65). As PV+ FSNs have been shown to play an important role in the 
generation of gamma oscillations (66-68) it is necessary to study the role of these inhibitory INs 
and their influence on PNs to understand typical cortical information processing, as well as 
changes in cortical information processing during neurodegeneration. 
 
 
Figure 2. The two working models of gamma oscillations. I) Interneuron-Network gamma (ING) model, according 
to which a network of GABAergic parvalbumin-expressing (PV+) fast spiking interneurons (FSNs) or basket cells 
mutually inhibit each other to produce gamma oscillations, although a minimal involvement of glutamatergic 
pyramidal neurons can be observed. II) Pyramidal-Interneuron Network Gamma (PING) model, according to 
which both glutamatergic pyramidal neurons and GABAergic PV+ FSNs or basket cells, by virtue of mutual 
excitation and inhibition, produce gamma oscillations. Figure adapted from (69).  
In vitro hippocampal gamma oscillations 
While studying in vivo gamma oscillations is more relevant for clinical applications, in vitro 
models of oscillations allow for easier control of variables that modulate oscillations and 
provide better access to individual cells. One of the key aspects of reliably verifying in vitro 
models of gamma oscillation is to replicate the observed features and mechanistic insights in 
vivo. In vitro models of gamma oscillation have shown that PNs have a low firing probability 
during ongoing gamma oscillations (58, 60, 70). These findings have been verified for in vivo 
models (59, 71). Similarly, in vitro studies have shown that perisomatic targeting PV+ FSNs or 
basket cells are essential for generating gamma oscillations (58, 72). These reports were also 
verified in vivo using optogenetic activation of PV+ INs (73). In vitro models arguably provide 
a prototype for in vivo physiological manifestations, however they have some limitations, as 
discussed in the conclusion of this thesis. Gamma oscillations are likely the most studied in 
vitro neuronal oscillation in the hippocampus and can be evoked through bath applications of 
carbachol (60) or kainic acid/kainate (KA) (74, 75) (figure 3). Carbachol generates gamma 
oscillations by activating the cholinergic systems, while KA triggers a generalized 
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depolarization which generates a sufficient excitatory drive to enable neuronal firing and 
synchronization in the gamma frequency band (74, 75). 
 
 
Figure 3. In vitro kainic acid/kainate (KA) induced gamma oscillations based on the chemical activation of KA 
receptors in a mouse hippocampal slice preparation. Figure adapted from (paper III).  
Many studies have investigated the mechanisms behind the generation of hippocampal gamma 
oscillations, looking at the cell types involved, their role in regulating the rhythm, and various 
factors influencing their functioning. In CA1, gamma oscillations have been observed 
originating from fast gamma oscillations propagated from the EC via the tempero-ammonic 
pathway, and also from slow gamma oscillations originating from CA3 via the SC (42, 60, 76, 
77). The EC has been shown to be vital for spatial navigation (78) and SC inputs from CA3 to 
CA1 have been shown to be important for memory consolidation (79). Some regions of the 
hippocampus have been shown to be intrinsically oscillogenic, such as the CA3 region (44, 59, 
80-82). Furthermore, a recent study has shown that CA1 is also capable of generating intrinsic 
gamma oscillation in response to a theta input in addition to inheriting activity from the 
projections received from CA3 and EC (83). Therefore, gamma oscillations in the hippocampus 
are thought to be an emergent property of the local circuitry within the hippocampus (60, 62, 
75, 83, 84). Studying the properties of oscillations within sub-regions of the hippocampus can 
provide great insight into normal brain functioning and brain disorders. 
 
2.3 Alzheimer's disease and network dysfunction 
Alzheimer’s disease is undoubtedly a global health priority given its burden on health systems 
and economies. Not only is AD the most common form of dementia in the elderly, it is also 
estimated to affect individuals who actively participate in the workforce (85). Alzheimer’s 
disease is progressive in nature and affected individuals may live for a long time with clinical 
symptoms. Signs and symptoms related to AD can be classified as pre-dementia, early, 
moderate, and advanced phases. Symptoms associated with AD are noticeably poor cognitive 
performance, learning and spatial navigation impairment and, in some cases, seizures and 
epileptiform activity (86, 87). Episodes of low cognitive function and heightened erratic 
neuronal activity are seen across various stages of AD and it is important to understand the 
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underlying mechanisms that cause them. Pathological changes in the brain may begin up to 20 
years before clinical AD symptoms manifest (88), by which time the cellular pathology is 
potentially too severe for any significant treatment. Current medications for AD can only 
alleviate symptoms and do not slow or stop the progression of AD. Diseases such as type-2 
diabetes and cardiovascular diseases are reported to occur concomitantly with AD and may 
increase the AD pathogenic process at a molecular level (89-91).  
Although AD was described more than a century ago, the molecular mechanisms underlying it 
remain largely unclear. Early pathological changes in AD are observed in the transentorhinal 
and EC, then spreading to the hippocampus, adjacent allocortical areas, and finally the 
neocortex (92). The severity and symptoms of the disease are associated with the 
aforementioned anatomical targets (92). Other important features of AD include cortical and 
subcortical atrophies that cause ventricular enlargement and the hypofunction of cholinergic 
neurons of the basal forebrain with the associated cognitive deficits (93, 94).  
Cortical electroencephalogram (EEG) recordings of AD patients have been reported to vary 
over a wide range of frequencies. A shift from fast to slow waves in spontaneous EEG 
recordings is typical, such as an increase in delta- and theta-frequency oscillations and a 
decrease in alpha- and beta-frequency (95-97). Numerous other studies suggest that there are 
alterations in gamma oscillations recorded in AD patients who have been clinically diagnosed 
as lacking long-term memory formation (98-101). Magnetic field tomography recordings 
showing reduced thalamocortical coherence of gamma oscillations in AD patients (46) and 
magnetoencephalography (MEG) recordings showing a loss in gamma-band synchronization in 
AD patients (50) have been reported. Electroencephalogram studies in rodent models of AD 
have suggested that degeneration of cholinergic neurons in the nucleus basalis (102, 103) 
contributes to the cognitive symptoms and the slowing of the EEG. 
Aberrations observed in AD, such as disturbed gamma oscillations, may be attributed to the 
two abnormal protein structures occurring in AD: i) intracellular neurofibrillary tangles (NFTs) 
that consist of hyperphosphorylated tau proteins; and ii) extracellular deposits of Aβ in the form 
of toxic soluble oligomers, fibrils, and plaques that may interfere with mechanisms driving 
neuronal oscillations. These two misfolded proteins are well known to cause the most 
significant loss of neurons and synapses (104, 105). The majority of AD research has focused 
on these two hallmarks and provided generous insight into how they influence neuronal 
function in AD. In particular, soluble oligomeric forms of A have gained importance in AD 
research owing to their heightened cytotoxicity and effects on synaptic functions (106-110). 
Several studies have directly linked acute exposure to Aβ to loss of functions such as neuronal 
oscillations in various brain regions (108, 109, 111-114). An inquiry into this misfolded 
protein’s potential role in network dysfunctions will greatly aid the design of therapeutic 
interventions aimed at preventing and/or rescuing neuronal dysfunction. The studies included in 
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this thesis aim to understand aberrations in neuronal network dynamics associated with acute 
Aβ exposure and investigate methods for their prevention. 
 
2.4 Amyloid-β peptide 
Histopathological examinations show that the brains of individuals with AD are characterized 
by a large number of extracellular deposits of Aβ, mostly in the cortical neuropil and blood 
vessel walls (115). The observation of extracellular Aβ is consistent with the fact that Aβ is an 
extracellular proteolytic cleavage product of the transmembrane amyloid precursor protein 
(APP), prevalent in the synapses of neurons (116). The sequential proteolytic processing of 
APP by β- and γ-secretase produces Aβ peptides of 36–43 amino acids in length and releases 
them into the extracellular space (117-119). Extracellular deposition of Aβ is well established 
and in vitro studies using extracellular applications of biochemically identified and isolated 
oligomeric forms of Aβ in physiological concentrations (120, 121) have shown induced 
alterations in synaptic plasticity and synapse formation (106, 122, 123). Apart from 
extracellular Aβ, careful examination of the lumens of multivesicular bodies and other types of 
intracellular vesicles has revealed the presence of intraneuronal Aβ (124-126). The existence of 
intracellular Aβ may occur through the secretory and endosomal pathways associated with the 
proteolytic cleaving of APP which provides an entry point to the cellular interior and the 
endosomal/lysosomal pathway, reported to cause lysosomal leakage (127). The existence of 
intraneuronal Aβ is associated with the disruption of cytosol and the interruption of 
mitochondrial function (128) Moreover, it is a pathological driver for AD progression (129). 
Therefore, it is important to discern whether observed synaptic dysfunctions and neurotoxicity 
principally arise from intracellular Aβ and/or extracellular Aβ.  
Of the two main isoforms of Aβ associated with AD, Aβ1-40 and Aβ1-42, Aβ1-42 in particular 
seems to be most active in AD, as it shows the strongest propensity for spontaneous 
aggregation and is more fibrillogenic (130). Both isoforms have been identified in senile 
plaques in the brains of patients with AD (131). Studies have shown that Aβ aggregates have 
deleterious effects on brain function and are associated with early cognitive decline in AD 
(132). One of the properties of Aβ peptides is the propensity to self-assemble or polymerize, 
forming dimers, trimers, and higher-order oligomers, which are variably toxic in each state and 
cause neuronal death (133, 134) (figure 4). There are also recent reports that the surface of the 
fibrillar form of Aβ provides a catalytic substrate for monomeric forms of A to form 
deleterious oligomers (135). This is known as the secondary nucleation theory and is discussed 
in greater detail in the results. The aggregated, water-soluble oligomeric forms of Aβ1-42 have 
gained importance in research for their cytotoxic effects (126, 136), direct link to the affected 
synaptic function (132, 137), and other pathologic relevance for AD. The mechanism of Aβ-
induced toxicity has been studied extensively and several perspectives have been put forth, 
such as the activation of inflammatory effects through interaction with the membrane (138), 
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induction of oxidative stress (139) by forming metal-Aβ complexes (140, 141), disruption of 
receptors’ function by binding to them (142), forming of membrane pores that lead to 
alterations in ionic homeostasis (143-145), and modification of DNA structures through 
attachment (146). 
 
 
 
Figure 4. Amyloid-β polymerization steps: from monomeric form to transient soluble oligomeric, small 
oligomeric, protofibrillar, and fibrillar forms. The secondary nucleation theory suggests that an interaction of 
monomeric Aβ on the fibrillar surfaces produces more oligomeric forms, making Aβ polymerization a cyclic event. 
Figure adapted from (147). 
 
Aβ in neuronal networks 
The cellular pathology that underlies network dysfunction during AD, especially neuronal 
oscillations, is not well understood and is an exciting area for exploration. An important 
question for AD research is how Aβ assemblies affect different classes of neurons and synapses 
(figure 5). Determining the answer will substantially help in predicting the effects of Aβ on 
neuronal circuit function (148, 149) in relevant brain areas such as the hippocampus.  
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Figure 5. Amyloid-β is reported to cause abnormal patterns of neuronal activity in microcircuits and neuronal 
networks. Amyloid-β is known to differentially affect the functioning of pyramidal neurons (PNs) and inhibitory 
cells (INs) and their synapses, causing an imbalance in network activity. Figure adapted from (150).  
 
There have been reports that Aβ forms ion-permeable pores in the neuronal membrane, thereby 
causing alterations in cellular homeostasis, leading to cell death (151-153). This may be 
concurrent with reported mechanisms wherein Aβ is suggested to cause aberrant synaptic 
changes and degeneration.  
Examinations of the brains of patients with AD have consistently revealed abnormalities in 
synapses: quantitative ultrastructural and immunohistochemical examinations from post 
mortem studies (154-158) have reported the loss of a significant number of synaptic boutons in 
the neocortex and hippocampus of AD patients compared to age-matched healthy individuals. 
Several studies have reported that synthetic Aβ oligomers can impair the molecular processes 
involved in long-term potentiation (LTP), leading to its significant disruption in hippocampal 
slices (159-162). It has also been reported that oligomeric Aβ, extracted from the cerebral 
cortex of brains from individuals with AD, depresses LTP and enhances long-term depression 
(LTD) in rat organotypic hippocampal cultures (107). 
In other studies, Aβ has been shown to change calcium homeostasis, leading to heightened 
neuronal excitability. This has been confirmed by many studies in which Aβ peptides have 
been shown to increase the cellular influx of calcium, causing excitation (163-166) and 
resulting in pre- and postsynaptic modifications (167). In vivo studies in human amyloid 
precursor protein (hAPP)-expressing mice have reported anatomical and biochemical 
alterations of the DG that bear resemblance to rodent models of epilepsy or neuronal 
overexcitation (168, 169). Similarly, video EEG recordings in freely behaving hAPP-
expressing mice have shown cortical and hippocampal epileptiform activity (169-172). Studies 
have also shown that A-induced neuronal hyperexcitability is responsible for the epileptic 
phenotype in AD mice models (86, 170). A clinical study has reported that hippocampal 
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hyperactivity is associated with increased chances of cognitive dysfunctions in patients with 
mild cognitive impairment and targeting hippocampal hyperactivity has therapeutic potential 
(173).   
Moreover, in electrophysiological studies focusing on two glutamatergic synapses in the 
hippocampus, the CA3-SC-CA1 synapse and EC-perforant path-DG granule cell synapse, A 
has been reported to suppress transmission strength and short/long-term plasticity (149). It is 
interesting to note that many studies have also reported that Aβ causes a marked reduction in 
neuronal network rhythmic activities. An example is the focal injection of Aβ into the 
hippocampus of rats, resulting in a decrease of theta oscillations along with a decline in 
cognitive performance (174). Similarly, acute exposure to Aβ reduced rhythmic activity to theta 
frequencies for GABAergic neurons (175) and glutamatergic neurons (153), wherein Aβ is 
suggested to have caused a functional loss of network activity rather than a structural deficit 
following the exposure. Oligomeric forms of Aβ have also been demonstrated to slow sensory-
induced theta rhythms (176), where the intraventricular injection of Aβ was directly associated 
with a slowing of oscillatory activity induced by sensory stimulation. This is in agreement with 
alterations of evoked theta oscillations in patients (177). Gamma oscillations have been shown 
to form long-term memory in rodents (178). Furthermore, in slices from human amyloid 
precursor protein (APP) Swedish (SWE) mutation (TAS10) mice, hippocampal gamma 
oscillations have been shown to be suppressed (179). The administration of oligomeric Aβ has 
also been shown to impair KA-induced beta oscillations (180). Consistent with these findings, 
in vitro hippocampal oscillations have been shown to decrease in aging mice (181). This leaves 
us with the question whether Aβ affects neuronal function in different ways, either by acting as 
an excitotoxin that aberrantly heightens excitability and/or acting as a suppressor of neuronal 
and network function. 
An important aspect to examine is whether Aβ causes dysfunction in INs and, if so, what the 
mechanisms are. One hypothesis is that Aβ impairs the synaptic function of INs more than PNs 
at the network level, whereby disinhibition and overexcitation occurs, rather than suppression 
(150). A similar effect can be expected if Aβ suppresses excitatory-inhibitory synapses more 
than excitatory-excitatory synapses (150). It has been noted that Aβ causes the impairment of 
PV+ IN activity by decreasing sodium channel activity, leading to epileptic seizures (182). 
Interestingly, the same study also showed that A-induced epileptiform activity in hAPP mice 
are correlated with reduced gamma activity (182). Another study with Sprawley-Dawley male 
rats demonstrated that KA-induced epileptiform spikes desynchronized and reduced fast 
gamma activity through an “anti-binding” mechanism (183). The heightened, aberrant 
excitability of individual neurons likely results in the disruption of firing rates and synaptic 
properties that underlie the strength of gamma oscillations. 
Clinically documented comorbid cases of AD and epilepsy have been reported (184-186). 
There is a strong relation between the occurrence of epilepsy and early-onset AD, particularly, 
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autosomal, dominant pedigrees suggest the potential role of high A levels and cytopathology 
(150). A has also been shown to increase met-enkaphalin levels in the hippocampus and EC, 
which could suppress inhibitory IN activity by activating µ-opoid receptors (187). It can thus 
be hypothesized that in AD and AD animal models compensatory inhibitory mechanisms that 
can delay and diminish excitotoxic processes may become dysfunctional, eventually leading to 
the loss of synapses and neuronal death. However, compelling and direct evidence is lacking to 
prove whether A overly and/or moderately affects the neuronal activity of INs. A strong 
reason exists to examine in detail the underlying molecular mechanisms of Aβ-induced 
aberrant neuronal functions and postsynaptic currents (EPSCs and IPSCs). This thesis attempts 
to fulfill this task. 
 
2.5 Therapeutic interventions aimed at Aβ-mediated neurotoxicity in neuronal networks 
Since AD is a slowly progressing and dynamic disorder, different mechanisms may guide 
different stages of the disease. For this reason, therapeutic interventions should be aimed at 
mechanisms at various stages of the disorder. One current therapeutic measure aims to maintain 
the level of A production by inhibiting the enzymatic steps (- and -secretase activity) 
required to cleave APP to A. Another approach is to enhance clearance of A (188).  
However these measures failed to produce successful clinical trials results even though they 
showed successful results in pre-clinical investigations (189-191). It is, however, uncertain 
whether these strategies in fact lower levels of A to the extent that would protect the neuronal 
network. Detrimental effects of A on adult granule cells have been shown to be prevented by 
inhibiting GABAA receptors during early stages of adult neurogenesis or by enhancing 
glutamatergic signaling during later stages of maturation (192). A potential method to counter 
A-induced aberrant network excitability and hypersynchronization is yet to be discovered and 
the effects of antiepileptic drugs on AD patients are not yet understood (86, 150, 182). The 
other pathogenic hallmark of AD, endogenous tau, may also influence the detrimental effects of 
A through interactions or synergistic actions, as they are both compartmentalized in neurons 
(193, 194). As A can form toxic oligomers and higher fibrillar forms, A polymerization 
inhibitors have been suggested to protect neuronal network functions. Ligands designed to bind 
and stabilize the 13–26 region of A in an -helical conformation have been shown to reduce 
A toxicity in cell cultures and hippocampal slice preparations (114). It has also been shown 
that KCNQ channel dysfunction is associated with decreased medial-septum theta oscillations 
(153). D. Melanogaster expressing human A1-42 in the CNS, when exposed to these ligands 
exhibited a prolonged life span, increased locomotor activity, and reduced neurodegeneration, 
suggesting that stabilizing of the A -helix may counteract polymerization to toxic assemblies 
by shifting equilibrium between the α-helical and β-sheet secondary peptide conformation 
towards the α-helical structure (114). For several decades, certain molecular chaperones have 
been known to play an important role in aiding in vivo folding of newly synthesized proteins in 
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their native states, trafficking to specific cellular locations, and the efficient assembly of 
molecular subunits to multimeric structures (195-197). Amyloid fibrils are found in a number 
of diseases and it has been shown that the C-terminal domain of the lung surfactant protein C 
(SP-C), ProSPC (CTC), has anti-amyloid effects (198, 199). It was suggested that CTC 
functioned as a chaperone that acted preferentially against amyloid fibril formation (200), thus 
influencing later stages of the Aβ aggregation sequence, limiting fibril formation. Similarly, 
Bri2 BRICHOS, another molecular chaperone that is ubiquitous in the CNS, has been shown to 
prevent Aβ-induced cellular and network changes and may have potential as a future 
therapeutic intervention tool in AD (201, 202). 
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3 AIMS 
 
The overall goal of the studies included in this thesis is to understand the cellular-, synaptic-, 
and network-level changes caused by Aβ in mouse hippocampus in vitro, identify the cytotoxic 
step/steps in the Aβ aggregation process that causes these changes, and attempt to prevent these 
changes using Aβ-binding ligands and chaperone peptides that delay A aggregation into toxic 
forms such as oligomers and fibrils. 
I) Examination of acute effects of different Aβ assemblies on major hippocampal cell 
classes and network function: How are glutamatergic and GABAergic neurons 
affected by different Aβ species and what are the consequences for the functional 
dynamics in the hippocampal network? 
II) Identification of the exact cytotoxic step in the Aβ peptide (mis)folding sequence and 
investigation of the folding and aggregation mechanisms responsible. 
III) Assessment of strategies aimed at preventing and/or rescuing Aβ-induced cellular and 
network changes. Use of Aβ-binding ligands and molecular chaperones known to 
prevent/delay Aβ fibrillization. 
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4 MATERIALS AND METHODS 
 
This section provides a detailed account of the rationale behind the materials and methods used 
in the studies contained in this thesis.  
 
4.1 Ethical Considerations 
 
All experiments were performed in accordance with ethical permits issued to Dr. André Fisahn 
by the regional ethical board in Sweden (Norra Stockholms Djurförsöksetiska Nämnd). 
Experiments were carefully considered to maximize results with a minimum number of animals 
used. This was done by, for instance, sharing brain tissue from one animal amongst several 
researchers in the lab. Though we minimized animal use, the question as to whether or not 
animals need to be used for scientific experiments should be addressed. As our experiments 
focused on neuronal network functions which cannot be elicited in cell lines or non-animal 
based systems, we were limited to using animals with complex and well-established neuronal 
networks that can approximate human brain functions. Neuronal oscillations, as discussed, are 
an integral part of normal brain functioning and are also affected by neurodegenerative 
disorders. They can be pharmacologically elicited in vitro in brain areas such as the 
hippocampus, septum, and other cortical regions. This in vitro approach offers several 
advantages for addressing our aims such as: 1) reduced long-term animal suffering when 
compared to in vivo recordings; 2) relatively fewer experimental animals are used, as the tissue 
samples obtained can be used for multiple experiments per brain and shared between several 
investigators; 3) good access to neuronal networks and individual neurons for LFP and 
intracellular recordings; 4) direct pharmacological manipulations and stable long-term 
recordings of gamma oscillations; 5) the possibility to study neuronal networks from an area of 
interest in isolation. 
 
4.2 Animals 
 
Our model for AD studies is the acute exposure of Aβ to both quiescent and activated 
hippocampal slices of C57BL/6 mice of either sex (postnatal 14–30 days) in all experiments. 
The use of experimental mice gives us several advantages as the majority of AD research has 
centered on mice models of various types, including transgenic types, which show a great level 
of AD-like phenotypes (169, 172, 182, 193, 203). Genetically-modified mice that are green 
fluorescent protein (GFP)-labeled for PV+ (204, 205) also simplify finding and recording the 
activity of PV+ FSNs in neuronal network dynamics (182, 183). For the purpose of the 
enclosed projects, wild-type and PV+ mice were used. Acute exposure of Aβ to hippocampal 
 20 
 
slices is a common way of studying electrophysiological properties that are associated with 
cells and neuronal networks (179). A1-42 was the only form of A used in all our experiments 
and is referred to as simply ‘A’ in this thesis.   
 
4.3 Tissue preparation and recordings 
 
All animals were anesthetized using isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-
ethane) before decapitation. The brain was dissected and kept in a cold artificial cerebrospinal 
fluid (ACSF) that was modified for dissection (please refer to the enclosed papers for the 
various ACSF compositions). Horizontal sections with a thickness of 350 µm were cut from the 
ventral hippocampi of both hemispheres using a Leica VT1200S vibratome (Leica 
Microsystems) and were immediately transferred to a humidified, oxygenated interface 
chamber and allowed to recover for a minimum of 1 hour. For experiments exclusively aimed 
at examining gamma oscillations, slices were transferred to submerged chambers which either 
had Aβ (Aβ slices) of a desired concentration and exposure time or not (control slices). 
Recording of gamma oscillations were performed in the interface-styled recording chamber 
(figure 6). All experiments were performed with parallel controls from the same animal brain 
hippocampal preparation.  
 
 
Figure 6. A schematic representation of experimental procedure to compare the unpaired data sets of A-exposed 
and control gamma oscillation recordings in an interface chamber.  
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Local field potential recordings 
Local field potential recordings were carried in an interface recording chamber in which slices 
were superfused at 34°C with ACSF modified for the optimum recording condition (please 
refer papers for composition) at a rate of 4–7 ml/min and continuously bubbled with 95% 
oxygen and 5% carbon dioxide to ensure adequate oxygenation for slice health. Gamma 
oscillations were elicited by superfusing KA (100 nM) for at least 20 min to allow slices to 
stabilize; recordings were carried out in hippocampal area CA3 stratum pyramidale with 
ACSF-filled borosilicate glass microelectrodes pulled to a resistance of 3–5 . It should be 
noted that in vivo CA3 gamma oscillations have a peak frequency of ~30–40 Hz, however, in 
vitro, the peak frequency of gamma oscillations is usually somewhat lower owing to its 
dependence on the recording temperature (206). Electrophysiological recordings at room 
temperature for a long period of time cause early cell death, therefore the recording temperature 
is often kept around 34°C. Gamma oscillation experiments examining the effects of A- 
binding ligands and molecular chaperones on various forms of A were designed to pre-
incubate A and the molecular tool in the submerged chamber, similar to the method shown 
in figure 6, before transfer to the interface recording chamber. The idea being that these 
molecular tools act on A at different temporal points in its folding and polymerization 
process (figure 7).  
 
 
Figure 7. Prevention strategies of A polymerization. Use of A-binding ligands that stabilize -helical 
conformation over -sheet conformation and molecular chaperones that delay the process of fibrillization.  
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Single-cell experiments 
Experiments examining single-cell events and concomitant extracellular recordings were 
carried out in a submerged recording chamber. A K-gluconate based intracellular solution 
(refer to papers for composition) was used for the single-cell whole-cell patch clamp 
recordings. ACSF was used as an intra-pipette solution for extracellular LFP and cell-attached 
recordings. PN and FSN AP firing were recorded using a non-invasive, cell-attached recording 
mode, with cell-attached configuration obtained after establishing a giga-ohm seal between the 
recording pipette and cell membrane. APs were detected as capacitance transients in voltage-
clamp mode. For experiments examining synaptic currents, whole-cell patch clamp with a K
+
 
channel-blocking, Cs
+
-based, 10 mM Cl
− 
intrapipette solution was used (please refer to papers 
for composition). Excitatory postsynaptic currents were recorded at a holding membrane 
potential (Vh) of -70 mV and IPSCs were recorded at a Vh of 0 mV. For experiments looking at 
the synaptic properties of FSNs, a gramicidin-based perforated patch recording was used. The 
main difference between a perforated patch and whole-cell patch clamp is that a perforated 
patch uses an antibiotic agent, such as gramicidin, which forms small pores in the cellular 
membrane. The gramicidin patch clamp method has several advantages over the whole-cell 
method, such as allowing for the equilibration of only monovalent ions between the patch 
pipette and the cytosol while maintaining endogenous levels of divalent ions, such as Ca
2+ 
and 
signaling molecules (207, 208), making this method mostly non-invasive. The gramicidin-
based perforated-patch pipette solution consisted of KCl, NaCl, MgCl2, and KOH (140 mM, 10 
mM, 1 mM, and 10 mM, respectively), to which 50 mg/ml gramicidin was added. 
 
4.4 Recording protocol and data analysis 
 
Local field potential recordings in the interface chamber were carried out with a 4-channel 
amplifier M102 (Electronics laboratory, Faculty of Mathematics and Natural Sciences, 
University of Cologne, Cologne, Germany) and conditioned using a HumBug 50 Hz noise 
eliminator. Submerged LFP and patch clamp recordings were carried out using a Multiclamp 
700B amplifier where data was sampled at a rate of 10 kHz. A Digidata 1322A digitizer and 
Clampex 9.6 software (Molecular Devices) were used. The protocols used for spontaneous and 
activated LFP, PSC, and AP recordings were in gap free current clamp mode. Patch clamp 
recordings were performed on PNs identified by their firing patterns in response to a series of 
current injection steps (200 ms); FSNs were identified by GFP fluorescence in slices from 
PV-GFP mice (204, 205) and confirmed by their firing patterns. Fast-spiking INs were 
segregated from non-FSNs counterparts by their distinct firing profile and action potential 
shape. 
All data were analyzed using Axograph X (Kagi, Berkely, CA, USA), Kaleidegraph (Synergy 
software), and IGOR Pro (Wavemetrics). Gamma oscillations/LFP recordings were estimated 
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as power spectral density plots (from 60 second-long recordings) calculated as averaged 
Fourier-segments of 8192 points using Axograph X in all the papers (I, II, III and IV). The 
power of oscillations was calculated by integrating the power spectral density between 20 and 
80 Hz using Kaleidegraph and data are reported as means ± standard error of mean (SEM) in 
the texts and as median and upper/lower quartile in the figure box plots in papers I, II and III. 
The power spectral density between 20 and 80 Hz in paper IV is represented as bar graphs. For 
unpaired (non wash-in) experiments, Mann-Whitney U tests (two-tailed) were used; and for 
paired (wash-in) experiments of gamma oscillations, Student’s t tests were used. All levels of 
significance were reported as * p<0.05; ** p<0.01; *** p<0.001.  
For the total quantification of single-cell experiment recordings, total values were averaged 
over a 5 min period post 15 min of A application compared with the average of a 5 min initial 
control period in paper I. All data are presented normalized to the average of a 5 min initial 
control period. Postsynaptic currents (charge transfer, event amplitude, event frequency) were 
analyzed using custom macros in IGOR Pro and the normalized results represented average 
values taken over 1 min periods. Paired pulse ratio was defined as the first EPSP slope divided 
by the second EPSP slope. Student’s t test was used as the statistical tool for paired data of 
patch-clamp recordings where *p<0.05, **p<0.02, and ***p< 0.01. 
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5 RESULTS AND DISCUSSION 
 
5.1 Paper I 
Paper I investigates the mechanisms underlying the degradation of gamma oscillations caused 
by acute application of Aβ and tests potential methods to prevent this degradation. 
Study of Aβ effects on gamma oscillations 
We initially established the power of a stable, control gamma oscillation in the CA3 region of 
the hippocampus by washing in 100 nM KA for over 20 min. The power of these oscillations 
served as the control and was compared with the power of gamma oscillations from slices pre-
incubated with high-purity recombinant Aβ1-42 (containing a mix of conformation states of 
oligomeric, pre-fibrillar, and fibrillar Aβ) of varying concentrations (2 nM, 50 nM, 500 nM, 1 
µM) for varying lengths of time (15 min, 30 min, 60 min, 120 min and 180 min). 
When incubated for 180 min with a physiological concentration of Aβ (50 nM), the power of 
gamma oscillations was significantly reduced to 20% of the control. Further increases in the 
concentration of Aβ resulted in proportionally further reductions in the power of gamma 
oscillations. After trying several concentrations and incubation times of Aβ, we found that 
incubation with 50 nM Aβ for 15 min significantly reduced the power of gamma oscillations to 
55% of the control. We believe a paradigm of “50 nM Aβ for 15 min” is well suited to study 
cellular and network mechanisms underlying acute Aβ-induced degradation of gamma 
oscillations. In summary, our findings suggest that the Aβ-induced reduction of gamma 
oscillation power is incubation time- and concentration-dependent. Similar findings have been 
reported by our lab before, wherein 1 µM Aβ1-42-induced gamma oscillations degradation was 
observed in the hippocampus (114) and Aβ25-35 and Aβ1-40-induced the desynchronization of 
septal theta oscillations (153).  
Severity of Aβ effects increases with fibrillization 
We then aimed to examine which aggregation state of Aβ causes the most severe effects on a 
cellular and network level in the hippocampus. Soluble oligomeric forms of Aβ have gained 
importance in the recent past compared to fully fibrillized forms. We studied the effects caused 
by purified monomeric Aβ, by a mix of Aβ conformations, and by a fully fibrillized preparation 
of Aβ. We saw that preparations containing only fully fibrillized Aβ degrade gamma 
oscillations the most, followed by preparations containing a mix of Aβ conformations. 
Preparations containing purified Aβ monomeric resulted in the smallest, yet still significant, 
decrease in the gamma oscillation power. This suggests that as the rate of fibrillization 
increases, gamma oscillations reduce more strongly. One possible explanation would be that 
Aβ fibrils act as catalysts for the increased production of toxic oligomeric Aβ species according 
to recently described secondary nucleation kinetics (135) (figure 4). It has been shown that 
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when a purely monomeric preparation of Aβ is seeded with an otherwise innocuous amount of 
fibrillar Aβ, the cytotoxicity of the Aβ preparation is greatly increased because the formation of 
toxic oligomeric species increases on the catalytic surface of the seed fibrils (135).  
Study of Aβ effects at a single-cell level 
We tested the hypothesis that a possible desynchronization of AP firing in PNs could be the 
mechanism underlying Aβ-induced degradation of gamma oscillations. Pyramidal neurons in 
area CA3 were recorded in cell-attached mode with concomitant LFP recording. We observed 
that during the wash-in of Aβ there was a steady degradation in the power of gamma 
oscillations for about 15 min, after which it plateaued. Results revealed that along with this 
degradation in the power of gamma oscillations there was an increase in the AP firing 
frequency in PNs. This was paralleled by an increase in AP-gamma phase gaussian half-width, 
suggesting that Aβ desynchronizes PN firing in relation to the gamma rhythm. It has been 
shown that desynchronization of AP firing underlies the degradation of neuronal oscillations 
(153, 209, 210), suggesting it as the most likely mechanism behind the observed Aβ effect on 
gamma rhythms. It was reported that A25-35 induces an increase in input resistance (Ri) 
associated with membrane depolarization in CA3 PNs, suggesting a possible mechanism 
behind the increased PN firing we observed. Other studies have reported that A-induced 
neuronal hyperexcitability underlying AD epileptic phenotype (170) was a result of A-
induced depolarization of both the neuronal resting membrane potential (Em) and GABA-
mediated current reversal potential (EGABA), leading to aberrant network activity (86). It has 
also been reported that acute application of A to hippocampal slices causes a 
hyperpolarization of AP threshold and a reduction in after-hyperpolarization, leading to 
increased excitability (211).  
Aβ alters balance between excitation and inhibition 
Gamma oscillations depend on the tight regulation between inhibition and excitation in 
neuronal networks. Any change in this equilibrium will alter the characteristics of gamma 
oscillations. For this reason, we studied the effect of Aβ (1 µM) on EPSCs and IPSCs in CA3 
PNs. Our study suggests that both in the quiescent and the activated network (100 nM KA), Aβ 
acts to increase excitation (EPSCs) while suppressing inhibition (IPSC). The excitation change 
is based on an Aβ-induced increase of EPSC frequency and amplitude; and the inhibition 
change is based on an Aβ-induced decrease of IPSC frequency and amplitude. This suggests 
that Aβ alters the balance of excitation and inhibition independent of the state of the network 
(activated or quiescent). 
A recent in vitro study looking at the impact of acute A1-42 on inhibitory synaptic transmission 
in rat somatosensory cortex PNs confirms our results, reporting that A depresses the 
monosynaptic GABAA receptor-mediated IPSCs by 60% and indicates the synaptic site of A 
action (212). It was also shown that A-induced IPSC decline could be prevented with a 
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GABAA receptor internalization blocker, suggesting a possible mechanism of A, namely 
selectively weakening synaptic inhibition via the down-regulation of GABAA receptors (212). 
A was also shown to selectively impair IN excitability as well as inhibitory inputs to PN in the 
prefrontal cortex (213). 
Our electrophysiological recordings revealed that I-V (current to voltage) relationships were 
not associated with a change in cells’ Ri or an increase in leak currents (data not presented), 
leading us to believe there was little or no effect caused by Aβ forming cell membrane pores in 
our system, as reported in other studies (151, 214, 215). We believe that a more plausible 
mechanism of A-induced aberrant cellular functioning is the increase in PN firing rate and an 
increased post-synaptic excitability underlying the observed degradation of gamma oscillations  
How exactly the acute application of A induces these electrophysiological changes in PNs is a 
question which deserves further attention. Two possibilities include; i) A acting on the 
neuronal synapses, leading to the observed electrophysiological changes and/or ii) A acting 
onto neurons through certain receptors leading to the observed electrophysiological changes. 
Acute application of A is reported to cause a deficit in synaptic transmission and plasticity in 
hippocampal slices (106, 107). A is also reported to affect neurons, by acting on receptors 
such as nictonic acetylcholine receptors (216), glycine receptors (217), insulin receptors (218), 
and even internalized into neurons via a lipoprotein pathway (219). More recently, a study has 
suggested a possible involvement of the caveolin-endocytosis pathway mediating the 
internalization of A into neurons (220). Once internalized, Aβ could act as a pathological 
driver for AD, as there are accounts of intracellular A as a major component of A-induced 
alterations of glutamatergic synaptic transmission and plasticity (221). Both synapse 
concentrating A and intracellular A are known to cause cell death and ultimately lead to 
neurodegeneration (104, 108, 222). However, new studies should be designed to examine 
whether the A-induced electrophysiological changes observed can be attributed to the  
possibilities discussed above.  
Another aspect to examine is whether the Aβ-induced synaptic effects observed may be a 
consequence of cellular energy metabolism dysfunctions caused by Aβ (223, 224). Impaired 
glucose utilization, the lowering of cellular adenosine triphosphate (ATP) levels, and brain 
insulin resistance are also markers of AD (86). A could be acting in a way that results in the 
loss of cellular ATP content and impairs glucose use. Additionally, Aβ has been shown to 
impair insulin signaling and neuronal insulin receptors (225, 226). One study has reported that 
intrahippocampal administration of Aβ resulted in an impaired hippocampal metabolism and 
insulin signaling that led to a rapid impairment of spatial and working memory (227). It is also 
possible that the involvement of glucose impairment associated with dysfunctional insulin 
signaling may be an underlying factor for the observed synaptic effects caused by Aβ. 
Researchers have found that by supplementing glucose with other energy substrates in an AD 
mouse model, they were able to prevent A toxicity, hyperexcitability and LTP deficits (86). 
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Future studies should be designed in a holistic manner to better understand synaptic 
dysfunctions and the associated dynamics of energy metabolism both in vitro and in vivo and 
related to behavioral aspects. This may help in better strategizing therapeutic interventions for 
AD.  
Prevention of gamma oscillation degradation and preservation of excitatory/inhibitory 
balance using compounds that interfere with Aβ folding and aggregation 
As noted in the introduction, Aβ has the propensity to aggregate into larger, fibrillar forms. The 
secondary peptide conformation of monomeric Aβ changes from its α-helical form to a β-sheet 
form which can then polymerize into soluble oligomeric forms, then into protofibrils, and 
finally into the fibrils that accumulate into AD-typical plaques. There are several conformatory 
states of Aβ associated with its aggregation states. This knowledge is vital to determine the 
most cytotoxic conformations of Aβ. With recent insight into secondary nucleation 
mechanisms in the production of toxic oligomeric Aβ, therapeutic strategies aimed at 
stabilizing the secondary peptide structure of Aβ in its α-helical form and preventing later 
fibrillization are necessary. 
We used two classes of compounds that can interfere with the Aβ folding and aggregation 
sequence at different temporal points. Dec-DETA is a designed ligand that shifts the 
equilibrium of co-existing α-helical and the β-sheet secondary peptide conformations of Aβ 
towards α-helical forms (16, 34). It interferes at an early stage of Aβ folding and aggregation 
and limits the formation of β-sheets, which are a prerequisite for aggregation. The second group 
of compounds that we used was a recombinant human BRICHOS domain from a lung 
surfactant C precursor protein (ProSPC) which delays the aggregation of Aβ later than Dec-
DETA by preventing β-sheet-type peptides from aggregating. 
When Dec-DETA (250 nM) was incubated with monomeric and mixed Aβ (50 nM), we found 
that gamma oscillations were preserved at levels similar to the control. However, when Dec-
DETA was incubated with fibrillar Aβ, there was only a partial preservation of gamma 
oscillations. This may be due to the ligand’s inability to act fully on the predominantly 
fibrillized forms in their parallel β-sheet structure. On the other hand side the fact that designed 
ligands such as Dec-DETA have an effect on fully fibrillized Aβ at all evidences fibril turn over 
(i.e. breakdown into smaller soluble forms which the ligand can then interact with). When 
slices were incubated with the second compound, ProSPC BRICHOS (1 µM), and monomeric, 
mixed, and fibrillar forms of Aβ, similar results were obtained to those with Dec-DETA. 
Our next aim was to test whether the preventative actions of these ligands on Aβ-induced 
gamma degradation were mirrored in cellular characteristics. As discussed concerning altering 
the excitatory/inhibitory balance with Aβ, we investigated the effect of Aβ (1 µM) in the 
presence of either compound on IPSCs and EPSCs in CA3 PNs. To do so, EPSCs (Vh = -70 
mV) and IPSCs (Vh = 0 mV) were recorded from PNs during KA-induced gamma oscillations. 
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Analysis showed that both EPSC and IPSC charge transfer remained unaltered. Hence, we 
conclude that the protective effect of Dec-DETA and ProSPC BRICHOS on gamma oscillation 
is based on their ability to prevent A toxicity on a cellular and synaptic level.  
In summary, gamma oscillations are reduced through the interference by Aβ at its physiological 
concentrations. The basic mode of Aβ action in the CA3 PNs is to desynchronize the firing of 
APs and shift the balance between excitation and inhibition. We demonstrate that this kind of 
Aβ-induced cellular and network changes can be prevented using designed ligands and 
molecular chaperones that can bind Aβ early in its aggregation sequence, preventing/limiting it 
from forming toxic forms and interfering with gamma oscillations. The next study was 
designed to better understand the role of Aβ-binding ligands and molecular chaperones. 
 
5.2 Paper II 
Paper II examines whether a novel Aβ targeting, second-generation ligand AEDabDab is more 
efficient at preventing Aβ-induced degradation of gamma oscillations. In contrast to previously 
developed first-generation ligands such as Dec-DETA or Pep1b, AEDabDab contains the 
triamino acid, Nγ-(2-aminoethyl)-2, 4-diaminobutanoic (AEDab) acid. The ligand carries an 
extra positive charge in the side chain. It has been previously shown that peptide-like 
compounds containing an arginine stabilize the central helix of Aβ in the -helical 
conformation, thereby delaying its aggregation into neurotoxic species (114). Moreover, it has 
been shown that the oral administration of these inhibitors in D. Melanogaster expressing 
human Aβ1-42 resulted in prolonged lifespans, reduced locomotor dysfunction, and reduced 
neuronal damage (114). AEDabDab is designed to replace the arginine residue with the AEDab 
triamino acid for a better interaction with Aβ. This is supported by molecular dynamic 
simulations of the stability of the Aβ central helix with the new ligand. We hypothesize that the 
second generation ligands to be more efficient at preventing Aβ-induced degradation of 
gamma oscillations.  
Gamma oscillations were induced by superfusing horizontal hippocampal slices of C57BL/6 
mice with 100 nM KA. LFP recordings in the CA3 region were performed both in naïve slices 
(control) and in slices pre-incubated with Aβ. The studies showed that when A exposed slices 
were co-treated with Pep1b and AEDabDab separately and compared with control and Aβ 
slices, AEDabDab greatly prevented Aβ-induced reduction of gamma oscillations and showed 
a noticeably better ablative effect compared to the first-generation ligand Pep1b.  
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5.3 Paper III 
With paper III we wanted to expand on previous finding that the molecular chaperone ProSPC 
BRICHOS prevents or delays the catalytical cycle that produces neurotoxic Aβ oligomers and 
prevents Aβ-induced degradation of gamma oscillations. BRICHOS is a protein domain with 
roughly 100 amino acids and was identified in the proteins such as BRI, related to familial 
British dementia, chondromodulin associated with chondrosarcoma, and lung surfactant 
protein C (ProSPC) (199, 228). It has been shown previously shown that BRICHOS domain 
efficiently prevents amyloid fibril formation (198, 199). In this study, our collaborators show 
that the mode of action of ProSPC BRICHOS is the specific inhibition of the catalytical cycle 
and limiting of A toxicity by binding to the surfaces of A fibrils and redirecting the 
aggregation reaction to a pathway that produces minimal formation of toxic oligomeric 
intermediates. This is verified by monitoring live brain tissue by means of cytotoxicity and 
electrophysiological findings that we report as a measure for neurotoxicity. 
Kinetics of A aggregation  
The first part of the study monitored the kinetics of aggregation of A using analytical 
approaches where the rates of primary nucleation, fibril elongation, and secondary nucleation 
were predicted. The findings were in agreement with previous reports (135, 229). When A 
was tested in the presence of an excess of the BRICHOS domain, the data revealed that there 
was a complete inhibition of secondary nucleation. The findings also reveal that reduction in 
the rate of primary nucleation, fibril elongation, or secondary nucleation did not significantly 
affect the total quantity of mature fibrils formed during the polymerization process of A, but 
had a significant effect in limiting the generation of oligomers during reaction. This analysis 
confirms that the BRICHOS domain effectively prevents the formation of low molecular 
weight oligomeric species, thereby dramatically reducing the associated cytotoxicity. 
ProSPC BRICHOS site of action 
The second part of the study focused on determining which molecular species of A the 
BRICHOS domain chaperone acted on. To identify this, fibrillar A1-42 produced in the 
presence and absence of ProSPC BRICHOS was added to solutions of monomeric A. It was 
observed that pristine fibrils that were not exposed to ProSPC BRICHOS readily enhanced 
secondary nucleation and rate of polymerization. In contrast, fibrils that were exposed to 
ProSPC BRICHOS displayed a significant amount of the chaperone bound to the fibril surface 
during the A polymerization process. This was confirmed with transmission electron 
microscopy (TEM) visualization and surface plasmon resonance (SPR) studies, where the 
nature of interactions clearly indicated specific binding of the chaperone to the fibril surface.  
By combining kinetic studies and the binding affinities of A and the chaperone, it was clear 
that the chaperone binds to A fibrils with high affinity and specifically inhibits secondary 
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nucleation events that likely occur on the fibrillar surface. The study then examined the degree 
of inhibition of the production of low molecular weight oligomeric species by studying their 
concentrations during A1-42 aggregation in the presence and absence of the chaperone. The 
different molecular species of A such as monomers, small oligomers (about 14–65 kDa), and 
large oligomers (about 66–90 kDa) were eluted at different times and their ratio was 
determined using size exclusion chromatography (SEC). It was observed that the 
concentrations of oligomeric species were substantially reduced in the presence of the 
chaperone.  
Electrophysiological findings 
Our aim was to establish whether a reduction in the population of oligomeric species through 
the inhibition of the secondary nucleation pathway by ProSPC BRICHOS is sufficient to 
prevent A-induced degradation of gamma oscillations. Similar to our previous experimental 
designs, we compared the degree of A-induced degradation of hippocampal gamma 
oscillations in the presence and absence of ProSPC BRICHOS (1 µM) to control conditions. 
Our findings revealed that slices, when incubated with soluble monomeric A1-42, showed a 
significant but limited reduction in gamma oscillations as opposed to slices exposed to soluble 
monomers seeded with a small amount of pre-formed fibrils which showed a much larger 
reduction of gamma oscillations. This indicates that the toxic species were overwhelmingly 
produced by the fibril-catalyzed reaction. When the same conditions were used in the presence 
of ProSPC BRICHOS, we found that there was no degradation of gamma oscillations and the 
power of oscillations was comparable to control levels. The findings confirm our hypothesis 
that ProSPC BRICHOS may act to inhibit secondary nucleation of Aβ and that this may be a 
way of containing its neurotoxicity. This, along with other experiments looking at cell 
viability and cytoxicity measurements, suggests that the chaperone was able to inhibit 
toxicity associated with the oligomerization of Aβ. 
 
5.4 Paper IV 
In the previous paper, we report that the ProSPC BRICHOS domain may be a novel candidate 
in the search for AD treatments. However, the expression of ProSPC BRICHOS is restricted to 
alveolar type II cells, making it unable to interfere with deposition in the CNS (230). In the 
CNS, two other BRICHOS-containing proteins are expressed: Bri2 and Bri3, also referred to as 
integral transmembrane protein 2B (ITM2B and ITM2C). It has been shown that Bri2 and Bri3 
interact with APP and play a role in its processing in the formation of A peptides (201, 202, 
231); and it has been suggested that the fusion protein Bri2 BRICHOS may be a more effective 
delayer of A fibril formation than ProSPC BRICHOS based on their molar mass (199). In this 
paper, we test whether the Bri2 BRICHOS domain is a more potent inhibitor of A-induced 
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cytotoxicity and has a broader mode of action than ProSPC BRICHOS in an in vitro 
electrophysiological study and an in vivo model.  
Electrophysiological findings 
Much like previous experimental designs, we wanted to test whether Bri2 BRICHOS displayed 
properties similar to ProSPC BRICHOS in its ability to prevent A-induced degradation of 
gamma oscillations or, even, if it acted more efficiently. Bri2 BRICHOS and ProSPC 
BRICHOS (100 nM and 1 µM for both) were separately co-treated with slices exposed to A1-
42 (50 nM and 1 µM) for 15 min and 180 min. The power of gamma oscillations in these 
different conditions was then compared with conditions in the absence of the chaperones (A 
only) and control gamma oscillations. We observed that Bri2 BRICHOS more efficiently 
prevented A-induced degradation of gamma oscillations compared to ProSPC BRICHOS 
under the same experimental conditions (for details, please refer to paper IV).  
It is notable that both chaperones at a 100 nM concentration failed to prevent A–induced 
degradation of gamma oscillations when 50 nM A was co-treated with the chaperones for 180 
min and when 1 µM A was co-treated with the chaperones for 15 min and 180 min. This 
indicates that these molecular chaperones may only efficiently act on A at concentrations in a 
nanomolar range. This could be due to their instability, shedding off the surface of fibrils they 
interact with and becoming ineffective. Improved chaperone design may be required so that 
chaperones can act on the A fibril surface for longer periods of time.  
Supporting our electrophysiological findings, our collaborators showed that in vivo models of 
D. Melanogaster with transgenic expression of Bri2 BRICHOS in the CNS or the eye 
efficiently inhibited A toxicity. Following exposure of Bri2 BRICHOS, A diffusely 
distributed in mushroom bodies, an area involved in learning and memory, ProSPC BRICHOS 
forms punctuated deposits outside the mushroom bodies. Bri2 BRICHOS also inhibited several 
steps in A fibrillization pathways and functioned as a more efficient molecular chaperone than 
ProSPC BRICHOS. This suggests that Bri2 BRICHOS may be a more physiologically relevant 
chaperone for AD in the CNS and may be a better candidate for AD treatment. 
 
5.5 A-induced depolarization of CA3 Fast-Spiking interneurons (unpublished data) 
Fast-spiking interneurons fire synchronously and modulate PN activity through repetitive 
phasic inhibition (60, 62). The phasic inhibitions that FSNs exert on PNs determine the PN 
firing rate and phase during an ongoing gamma oscillation (210, 232, 233). It has been shown 
that the loss of FSN function is directly related to hyperexcitability and reduced gamma 
oscillations (182). Based on what we have shown in paper I, where acute application of Aβ 
resulted in reduced inhibition of CA3 PNs, it was crucial that we also examined any potential 
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Aβ-induced effect on FSNs, a major pre-synaptic source of PNs’ IPSCs. Hence, we 
investigated the effect of Aβ in FSNs in quiescent and network-activated slices. 
GFP-labeled PV+ FSNs were identified and firing rates of APs were recorded in quiescent 
slices as well as after KA-induced gamma oscillation. Our findings revealed that shortly after 
bath application of Aβ, the firing rates of FSNs increased dramatically during gamma 
oscillations, mirroring the Aβ-induced firing rate increase of PNs that we have shown in paper 
I. However, there was no significant change in the Em of FSNs in quiescent states after a wash-
in of Aβ recorded under perforated-patch clamp conditions, indicating a lack of 
hyperexcitability we observed in the same cell class during gamma oscillations. Therefore, we 
repeated the experiments, using synaptic stimulation to activate FSNs to their native firing rate 
(10 Hz) during ongoing gamma oscillations. It was interesting to observe that after the 
activation of FSNs, Aβ caused a significant depolarization in line with what was previously 
reported for DG granule cells and cortical pyramidal cells (86, 170). This was revealed by a 
shift in the I-V relationship of FSNs. The same stimulation in a control condition (absent A) 
failed to induce any change in Em.  
To summarize our previous and current findings of Aβ effects in PNs and FSNs, we show that 
Aβ causes i) an increase in PN and FSN firing rate, ii) an increase of EPSCs and a reduction of 
IPSCs in PNs, and iii) Aβ’s effect on FSNs is activity-dependent.  
A recent study has reported that Aβ significantly reduced IPSCs in CA3 PNs by 
downregulation of GABAA receptors (212). Hence, the increase in firing rates and reduced 
IPSCs in PNs could be explained by the Aβ-induced downregulation of GABAA receptors and 
A-induced post-synaptic depolarization. The observed Aβ-induced increase in FSN firing rate 
during a network-activated state and the lack of changes of FSN excitability in quiescent state 
could be perhaps explained by the activity-dependent depolarization of Em together with an 
increased excitatory drive on FSNs exerted by neighboring PNs in an activated-state.  
We need to further investigate the mechanisms behind A-induced depolarization of FSN Em, 
and how it may be modulated by activity-dependent A toxicity. Studies have shown that FSNs 
have high energy demands, larger metabolic inefficiencies, and increased vulnerability to 
metabolic deficits (234, 235). It has been shown that Aβ-induced depolarization of Em is 
through energy deprivation by glycolysis breakdown and such deprivation could be prevented 
by supplementing with alternative energy substrates (86).  Cortical FSNs are also relatively 
abundant in Na
+
/K
+ 
ATPase (236) and KATP channels (237, 238) compared to PNs. It will be 
interesting to study whether Aβ could be modulating FSN activity in an activity-dependent 
manner by causing metabolic aberrations and/or dysfunctional activity of specific channels in 
FSN and if these aberrations could be corrected by specific therapeutic interventions. 
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6 CONCLUSION 
 
6.1 Experimental constraints and future directions 
Electrophysiological recordings in living brain slices are probably the most widely used method 
to study the physiology of cortical structures today. Some common types of these in vitro 
studies are concurrent intracellular and extracellular recordings, two-photon calcium imaging, 
and voltage-sensitive dye imaging of layer-specific physiology of neurons and neuronal 
networks. All of these techniques have provided insight into the behaviors of cortical structures.  
Some of the shortcomings of in vitro brain slice preparations are that the slicing action itself 
damages tissue, the tissues are removed from the life-supporting supply of blood, the long-
range axonal inputs to cortical columns in the slices are severed (239), the life span of brain 
slices is limited, and sensitivity to oxygenation and flow rate of ACSF is evident (223, 240, 
241). The effects of decapitation-induced ischemia on the cell viability may be a problem. The 
artificial bathing medium (ACSF) that we use imperfectly matches compositions of the 
physiological CSF. The three most concerning factors in our experimental approach are; i) 
hippocampal slice preparations lacked vital projections from its nearby structures such as the 
medial septum (MS) which can modulate or contribute to hippocampal rhythmogenesis (242-
244), ii) the artificial activation of the neuronal network in isolated hippocampi to induce 
gamma oscillations do not recreate oscillatory activity that occurs in physiological conditions 
where external inputs are intact, and iii) the fact that we use young animals owing to easier 
single-cell recordings to study an age-related disease. Even though these factors are limiting 
factors, in vitro preparations are rapid, use relatively inexpensive animals, allow for direct 
visualization of slice structures and accurate placement of recording and stimulating electrodes 
in the desired substructures, and allow for easy pharmacological manipulations.  
If substantial and consistent observations are made from in vitro studies, certainly the next step 
is to design in vivo studies in intact animals where it is possible to correlate neuronal activity 
with sensory perception and behavior. Before detailing in vivo experimental designs, a number 
of aspects need to be examined. Given the knowledge we have about Aβ’s mode of action on 
the CA3 PNs and FSNs, it is essential to study the effect of Aβ on other subtypes of INs and 
PNs in other sub-regions of the hippocampus, such as CA1, the DG, and also structures that 
project into the hippocampus, such as the MS. These structures should be examined concerning 
the way they modulate gamma oscillations.  
It is important to examine the behavior of various cell types under the influence of Aβ and Aβ-
binding molecular tools in a combined septo-hippocampal preparation in both wild-type and 
mice overexpressing APP with Swedish and/or Arctic mutations (245-247). The projections 
from the MS to the hippocampus provide vital clues about synaptic transmission and neuronal 
oscillations in hippocampus (153).  
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With the latest advancements in optogenetic methods that express channelrhodopsin to form 
light-gated ion channels in MS, and with the use of laser excitation that influences hippocampal 
cells, acute application of A and A-induced effects in single cells and neuronal networks in 
the hippocampus would be an interesting aspect for continued research. If similar findings to 
those of the current thesis are made, it would also be interesting to use molecular tools that 
prevent A aggregation and toxicity.  
Different forms of Aβ are found in humans (248) and their roles in neuron and neuronal 
network function are not well understood. An experimental design that recreates the exact mix 
of these peptides as found in human AD patients with knowledge of the cytotoxic step in Aβ 
misfolding and the possible prevention/rescue with designed ligands and chaperones that 
prevent Aβ toxicity would strengthen our findings.  
In recent times, simultaneous neuronal recordings across cortical layers are achievable in vivo 
and the ability to replicate our in vitro findings in vivo will be a great accomplishment. 
Techniques such as two-photon in vivo imaging and calcium imaging provide the opportunity 
to monitor activities in awake animals and identify neurons for relatively long period of time 
(249-251). Using such techniques experimental designs that investigate long-term A effects in 
individual neurons and neuronal networks and cognitive aspects of rodent models of AD will 
essential for future research. A recent advancement has been deep layer, two-photon imaging 
using implanted microprisms into the cortex which enable the study of specific neuronal and 
neuronal network activity (239, 252, 253). This strategy combines optical access of ex vivo 
brain slice preparations and in vivo behavioral context and long-range connectivity that is 
relatively intact. Similarly, there are several in vivo studies of neuronal oscillations (254-257) 
that have given insight into physiologically relevant functions. A combination of these 
experimental approaches will likely enable us to better understand the acute and long-term 
effects of A at neuronal and neuronal network levels and also test whether A-binding tools 
are effective in reducing A-related toxicity.  
Another important aspect to study is the metabolomics of AD models, especially in relation to 
oscillatory functions and examining the dynamics of neurons and neuronal networks. Impaired 
glucose metabolism, insulin resistance, and neuroinflammation are all associated with AD (258, 
259). A recent study using triple-tracer small-animal positron emission tomography (PET) has 
reported that age-dependent microglial activation is associated with increases in amyloid loads 
as a sign of A-related neuroinflammation (260). These factors could influence the dynamics of 
neuronal oscillations; however, this is yet to be experimentally shown. Experiments designed to 
enhance the availability of energy substrates, ensure well-functioning insulin signalling, and 
reduce neuroinflammation in AD models could also potentially preserve neuronal oscillations. 
A holistic approach that ensures reduced A-related toxicity, a well-functioning glucose 
metabolism, insulin signaling, and reduced neuroinflammation is necessary in our attempt to 
rescue neuronal oscillations and sustain normal systemic brain functions. 
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6.2 Concluding remarks 
To conclude, the studies contained in this thesis likely serve as a prototype for cognition-
relevant gamma oscillations during AD progression in humans. We show that gamma 
oscillations are reduced when the neuronal network is exposed to pathological A peptides and 
that A acts by disturbing several intrinsic cellular mechanisms that help generate these 
oscillations. Two key observed features of the effect are: i) A causes an increase in AP firing 
properties of both PNs and FSNs and ii) Aβ causes a shift in the equilibrium between excitatory 
and inhibitory synaptic transmissions in PNs. We also show that such cellular- and network-
level aberrations can be prevented using special molecular tools such as A-binding ligands 
and molecular BRICHOS chaperones, known to prevent Aβ aggregation and toxicity.  
We believe our study provides new insights into how gamma oscillations may be affected in 
AD and suggest ways to preserve them. However, our findings require further confirmation 
through additional in vitro and in vivo experimental designs. Additionally, other important 
aspects, such as the examination of the function of various sub-types of neurons, synapses, and 
neuronal metabolomics, are necessary to preserve neuronal oscillations and better arrive at a 
translational research approach in attempts to cure AD. 
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